Investor Presentaiton

TCB-202-001 Summary and Conclusions TC BIOPHARM ▪ This study showed that ex-vivo expanded allogeneic yS T-lymphocytes derived from haploidentical donors is feasible with doses reaching level of 1 x 107 cells/kg body weight. ■ Infusions and repeat infusions of OmnImmuneⓇ were well tolerated with no DLTs and no Serious Adverse Reactions (SARS) or grade 3 treatment related toxicities reported in any of the patients who were treated in the trial ■ Two grade 2 IMP related AEs: 1 pyrexia, 1 raised C-reactive protein Preliminary evidence of the efficacy of OmnImmuneⓇ was observed with 1 CR and 1 MLFS at 28 days post IMP administration. 22 22

View entire presentation